News archive

In chronic lymphocytic leukemia (CLL), certain recurrent genetic alterations are known to influence disease progression and survival. One important abnormality is the loss of part of chromosome 11, del(11q), which is associated with a more aggressive disease course. However, it has remained unclear whether mutations in the ATM gene, which is also located in this region, have a similar impact.

RNA-sequencing has become a cornerstone in the study of gene expression, offering insights beyond mere mRNA transcript abundances. One area of increasing interest is alternative splicing, a process that allows a single gene to produce multiple transcript variants and thus protein isoforms with potentially different functions. In chronic lymphocytic leukemia (CLL), mutations in the splicing factor gene SF3B1 are well-documented, yet broader implications of SF3B1 mutations are underexplored.

The cost of whole-genome sequencing is approaching that of the traditional genetic tests currently used for patients diagnosed with acute leukemia, according to a new study published in the Journal of Medical Economics. With costs falling and whole-genome sequencing adding new information that can improve treatment decisions, researchers see a future in which whole-genome sequencing becomes the standard for acute leukemias.

Researchers from Karolinska Institutet have in collaboration with the University of Eastern Finland and Lund University a new publication in Genome Biology, demonstrated that targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia.

In a recently published review in the journal Biomarker Research, Joanna Zawacka, Docent at the department of Oncology-Pathology discusses our current understanding of p53 biology in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

Researchers at Karolinska Institutet and the University of Oslo present a new type of immunotherapy that attacks cancer cells with a specific mutation. A study published in the journal Nature Cancer shows promising effects on patient cells in mice and offers hope for patients with acute myeloid leukaemia (AML), a cancer that has proven difficult to treat.

A new Swedish study shows that whole genome sequencing can detect clinically relevant genomic abnormalities in acute lymphoblastic leukemia, ALL, and has great potential to be implemented in the diagnostic setting. The study was carried out by researchers within the Clinical Genetics group at the Department of Molecular Medicine and Surgery, the Genomic Medicine Sweden for haematology and published in the scientific journal Frontiers in Oncology.

Post-doctoral fellow Amos Tuval at the Department of Oncology-Pathology has been selected by the American Society of Hematology (ASH) to receive the 2023 ASH Global Research Award. Amos is one of 12 talented early-career investigators selected for this honor.

Researchers at the Department of Oncology-Pathology have together with researchers from The European Molecular Biology Laboratory published a paper in Nature Chemical Biology where they developed a method that can identify important differences between proteins in an unbiased way.

Next-generation sequencing studies have in recent years revealed numerous recurrently mutated genes in chronic lymphocytic leukemia (CLL). These mutations are usually found in a relatively small percentage of cases and associated with poor clinical outcome.

Researchers at Karolinska Institutet, among others, have studied the benefit of adding an established drug as a novel targeted therapy in the treatment of acute myeloid leukaemia (AML). The results suggest that the drug hydroxyurea can increase treatment efficacy at a relatively low cost. The results, which were published in the Journal of Internal Medicine, could have significant implications for cancer treatment, including in low-income countries.

Researchers at Karolinska Institutet, University of Oslo and Oslo University Hospital have developed a new kind of immunotherapy for leukemia. The results of a study published in Nature Biotechnology show that the therapy kills cancer cells from patients with acute lymphoblastic leukemia. The researchers now want to conduct a clinical study and also test the method on other types of cancer.

The Tobias Foundation grant in 2020 has been awarded to Magnus Tobiasson and Eva Hellström Lindberg, both researchers at Karolinska Institutet. The grant amounts to SEK 10 million over a five-year period. It will support research on early detection of relapse after stem cell transplantation for patients with myelodysplastic syndrome.

A new study has been initiated to evaluate whole-genome and RNA-sequencing as a first line diagnostic approach for patients in Sweden with acute leukemia. The study is conducted jointly by the national R&D platform Genomic Medicine Sweden and the biotech company Illumina – and is coordinated from Karolinska Institutet.

A common and inexpensive drug may be used to counteract treatment resistance in patients with acute myeloid leukemia (AML), one of the most common forms of blood cancer. This is the conclusion of a study in mice and human blood cells performed at Karolinska Institutet and SciLifeLab and published in the medical journal EMBO Molecular Medicine. The researchers will now launch a clinical study to test the new combination treatment in patients.

Researchers at Karolinska Institutet have explored NK cell-based immunotherapy on patients with treatment-resistant leukaemia. The study, which is published in the scientific journal Clinical Cancer Research, shows that the new therapy is effective against several types of leukaemia.